AZETIDINE COMPOUND AND PHARMACEUTICAL USE THEREOF

• US 20100331301A1
• Filed: 05/14/2010
• Published: 12/30/2010
• Est. Priority Date: 05/14/2009
• Status: Active Grant

• Current Assignee: Japan Tobacco Inc.
• Original Assignee: Japan Tobacco Inc.
• Inventors: Ogawa, Naoki, Ikenogami, Taku, Matsuo, Takuya, Matsumoto, Tatsuya, Yamasaki, Takayuki, Oka, Takahiro, Ikegashira, Kazutaka
• Granted Patent: US 8,765,739 B2
• Time in Patent Office: Days
• US Class Current: 514/210.18
• CPC Class Codes: A61P 1/00 Drugs for disorders of the alimentary tract or the digestive system
• CPC Class Codes: A61P 1/04 for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
• CPC Class Codes: A61P 13/12 of the kidneys
• CPC Class Codes: A61P 17/06 Antipsoriatics
• CPC Class Codes: A61P 19/02 for joint disorders, e.g. arthritis, arthrosis
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: A61P 19/10 for osteoporosis
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 35/02 specific for leukemia
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: A61P 37/02 Immunomodulators
• CPC Class Codes: A61P 37/08 Antiallergic agents antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07D 401/06 linked by a carbon chain containing only aliphatic carbon atoms
• CPC Class Codes: C07D 401/14 containing three or more hetero rings
• CPC Class Codes: C07D 405/14 containing three or more hetero rings
• CPC Class Codes: C07D 409/14 containing three or more hetero rings
• CPC Class Codes: C07D 413/14 containing three or more hetero rings

Abstract

Compounds of formula [I]:

wherein each symbol is as defined in the description,
or a pharmaceutically acceptable salts or solvates thereof.

Claims

1. A compound of formula [I]:

2. The compound according to claim 1:

wherein

R^b is

(1) C_1-6 alkyl group which may be substituted with the same or different 1 to 5 substituents selected from Group A,

(2) —

O—

(CH₂)_n1—

(O)_n2—

R^b1,

(3)

—

Y^c—

O—

R^b2,

(4) —

CH═

CH—

C(═

O)—

R^b3,

(5) —

NR^b4R^b5, or

(6)

3. The compound of formula [II] according to claim 1:

4. The compound of formula [III] according to claim 1:

5. The compound of formula [II-C] according to claim 1:

6. The compound of formula [III-B] according to claim 1:

7. The compound of formula [IV-A] according to claim 1:

8. The compound according to claim 1 which is selected from the group consisting of the following formulas or a pharmaceutically acceptable salt or solvate thereof.

9. A pharmaceutical composition comprising the compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.

10. A method of inhibiting colony-stimulating factor 1 receptor in a mammal, comprising administering to the mammal a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof.

11. A method of treating or preventing autoimmune disease, inflammatory disease, osteoporosis, osteolysis or cancer in a mammal, comprising administering to the mammal a therapeutically effective amount of the compound according to claim 1 or a pharmaceutically acceptable salt or solvate thereof.

12. The method according to claim 11, wherein the autoimmune disease rheumatoid arthritis, multiple sclerosis, or psoriasis.

13. The method according to claim 12, wherein the autoimmune disease is rheumatoid arthritis.

14. The method according to claim 13, wherein treating rheumatoid arthritis is done by preventing structural damage of joints.

15. The method according to claim 11, wherein the inflammatory disease is inflammatory bowel disease, glomerulonephritis, or diabetic nephritis.

16. The method according to claim 11, wherein the cancer solid cancer or blood cancer.